Multi-functional chimeric hematopoietic receptor agonists |
| 1. A hematopoietic protein comprising; an amino acid sequence of the formula: Met-1 R1-L1-R2, Met-2 ... |
|
DNA sequences comprising dystrophin minigenes and methods of use thereof |
| The present invention provides dystrophin minigenes that are significantly reduced in size without ... |
|
Pharmaceutical composition and method for hypermetabolic weight loss |
| The present invention relates to a device, pharmaceutical composition and method for metabolizing ... |
|
Method for manufacturing glycoproteins having human-type glycosylation |
| What is claimed is: 1. A method of manufacturing a glycoprotein having a sugar chain, comprising a ... |
|
Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores |
| What is claimed is: 1. A compound of the formula: ##STR2## wherein: a is from 0 to 6,: b is from 0 ... |
|
Nucleic acid analogue induced transcription of double stranded DNA |
| We claim: 1. A method of transcribing RNA, using a double-stranded DNA as a template, comprising: (... |
|
Peptide nucleic acid combinatorial libraries |
| OF THE INVENTION The synthesis of peptide nucleic acids (also known as PNA) via preformed monomers ... |
|
Nucleic acid-containing polymerizable complex |
| OF THE INVENTION The present invention is based on the development of a polymerizable complex ... |
|
|
Composition for treatment of and method of monitoring hepatitis C virus using interferon-TAU
| Details |
Inventors: Sokawa, Yoshihiro; Liu, Chih-Ping;
Assignee: Pepgen Corporation (Alameda, CA)
Primary Examiner: Mosher; Mary E.
Assistant Examiner:
Attorney, Agent or Firm: Mohr; Judy M., Perkins Coie LLP
A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase. |
|
DETAILED DESCRIPTION OF THE INVENTION I. Definitions Hepatitis C virus or HCV refers to the viral species of which pathogenic types cause Non-A Non-B Hepatitis (NANBH), and attenuated types or defective interfering particles derived therefrom. The HCV genome is comprised of RNA. RNA containing viruses have relatively high rates of spontaneous mutation reportedly on the order of 10-3 to 10-4 per incorporated nucleotide. Since heterogeneity and fluidity of genotype are inherent in RNA viruses, there are multiple types/subtypes, within the HCV species which may be virulent or avirulent. The propagation, identification, detection, and isolation of various HCV types or isolates is documented in the literature. Treating a condition refers to administering a therapeutic substance effective to reduce the symptoms of the condition and/or lessen the severity of the condition. Oral refers to any route that involves administration by the mouth or direct administration into the stomach or intestines, including gastric administration. OAS level refers to the concentration or activity of blood 2′,5′-oligoadenylate synthetase (OAS) protein. Recombinant host cells, host cells, cells, cell lines, cell cultures, and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities, are used interchangeably, and refer to cells which can be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to accidental or deliberate mutation. Progeny of the parental cell which are sufficiently similar to the parent to be characterized by the relevant property, such as the presence of a nucleotide sequence encoding a desired peptide, are included in the progeny intended yb this definition, and are covered by the above terms
|
| Related patents |
|
|
Anti-viral guanosine-rich oligonucleotides
In one embodiment of the present invention, there is provided a method of treating a pathophysiological state caused by a virus, comprising the step of administering a ...
|
|
|
Nucleic acid diagnostics based on mass spectrometry or mass separation and base specific cleavage
OF THE PREFERRED EMBODIMENTS The present invention is predicated in part on a base specific cleavage reaction to generate a set of small oligonucleotides bounded by the ...
|
|
|
Polymer microparticles for drug delivery
OF THE INVENTION The term microparticle is used herein to include nanoparticles. The microparticles preferably have a size in the range 10 nm to 200.mu.m. The water-...
|
|
|
Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
The present invention provides bioactive agents encapsulated in a rapidly releasing polymeric composition capable of inducing or potentiating an immune response and ...
|
|
|
Disaccharide derivatives for treating hyperglycaemia
The invention claimed is: 1. A drug composition comprising an active ingredient and a carrier in which said active ingredient is an amide or alkyl ester of an oxidized ...
|
|
|
Gene expression profiles in liver cancer
1. A method of diagnosing hepatocellular carcinoma in a human patient, compnsing: (a) detecting the level of expression in a tissue sample of ten or more genes from T...
|
|
|
Endovascular cardiac venting catheter and method
The present invention is directed to an endovascular approach for preparing a patient's heart for cardiac procedures which does not require a grossly invasive ...
|
|
|
Bone morphogenic protein-5(BMP-5) and DNA encoding same
OF THE INVENTION Purified human BMP-5 proteins are produced by culturung a host cell transformed with the DNA sequence of Table III. The expressed BMP-5 proteins are ...
|
|
|
Adipocyte-specific protein homologs
Within one aspect of the invention is provided an isolated polypeptide comprising a sequence of amino acid residues that is at least 80% identical to SEQ ID NO:2, ...
|
|
|
LSR receptor, activity, cloning, and uses for diagnosing, preventing and/or treating obesity and related risks or complications
The LSR receptor The invention relates to a purified LSR receptor (<<Lipolysis Stimulated Receptor>>), preferably hepatic, consisting of at least one .alpha....
|
|
|